Neurocrine Biosciences clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.
- Minor: NBI-1065890 Versus Placebo · Tardive Dyskinesia Trial sites expanded: 35 → 48 locations
- Notable: Rollover Study for Continuing Valbenazine Administration · Chorea Associated With Huntington Disease Reclassified as terminated (was completed)
- Minor: NBI-1065845 as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 106 → 120 locations
- Minor: Maintenance Effect of Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Interventions modified
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-12 | NCT07934303 Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET) | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 1 | |
| Phase 2 | 5 | |
| Phase 3 | 12 | |
| Phase 4 | 1 |
Disease areas by active trials
Depression (6) · Schizophrenia (6) · Bipolar Disorder (2) · Dementia (2) · Alzheimer's Disease (1) · Huntington's Disease (1)
Get alerts when Neurocrine Biosciences's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.